| | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Grant income | | $ | 2,966 | | $ | 1,215 | | $ | 10,463 | | $ | 13,407 | Less: | | | | | | | | | | | | | Clinical programs | | | 2,585 | | | 1,435 | | | 8,823 | | | 16,486 | Research and development personnel costs(1) | | | 1,691 | | | 1,248 | | | 5,043 | | | 6,221 | Preclinical programs | | | 396 | | | 37 | | | 1,078 | | | 262 | Manufacturing | | | 287 | | | 751 | | | 870 | | | 1,901 | Other research and development expenses | | | 30 | | | (5) | | | 122 | | | 222 | General and administrative expenses(2) | | | 2,040 | | | 2,387 | | | 6,999 | | | 7,307 | Equity-based compensation | | | 348 | | | 522 | | | 997 | | | 1,729 | Other segment items(3) | | | (266) | | | (230) | | | (822) | | | (577) | Segment and consolidated net loss | | $ | (4,145) | | $ | (4,930) | | $ | (12,647) | | $ | (20,144) |
(1) Research and development personnel costs exclude equity-based compensation (2) General and administrative expenses exclude equity-based compensation (3) Other segment items include, other income, net, and interest expense
|